Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Oils, Saffron
2. 8022-19-3
3. .alpha.-crocetin
4. Oils, Crocus Sativus
5. Saffron C.i. 75100
6. Nsc407300
7. Hsdb 1949
8. (2z,4e,6z,8e,10z,12e,14z)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioic Acid
9. 8,.psi.-carotenedioic Acid
10. Chembl1993367
11. Mfcd00064590
12. Zinc33985645
13. 2,6,8,10,12,14-hexadecaheptaenedioic Acid, 2,6,11,15-tetramethyl-
14. 2,6,8,10,12,14-hexadecaheptaenedioic Acid, 2,6,11,15-tetramethyl-, (all-e)-
1. Transcrocetin
| Molecular Weight | 328.4 g/mol |
|---|---|
| Molecular Formula | C20H24O4 |
| XLogP3 | 5.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 8 |
| Exact Mass | 328.16745924 g/mol |
| Monoisotopic Mass | 328.16745924 g/mol |
| Topological Polar Surface Area | 74.6 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 608 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 7 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
EXPL THER The antitussive activity of Crocus sativus stigma and petal extracts and its components, safranal and crocin, was evaluated using the nebulized solution of citric acid 20% in guinea pigs. The extract and agents were injected intraperitoneally. The ethanolic extract of C. sativus (100-800 mg/kg) and safranal (0.25-0.75 mL/kg) reduced the number of cough. The ethanolic and aqueous extracts of petal and crocin did not show antitussive activity. /Extracts of Stigma Croci/
PMID:16814486 Hosseinzadeh H, Ghenaati J.; Fitoterapia. 77 (6): 446-8 (2006)
EXPL THER Crocus sativus L. (saffron) is used in folk medicine, for example as an antiedematogenic agent. /The authors/ aimed to evaluate the antinociceptive and anti-inflammatory activity of saffron extracts in mice. /They/ used aqueous and ethanolic maceration extracts of Crocus sativus L. stigma and petals. Antinociceptive activity was examined using the hot plate and writhing tests. The effect of extracts against acute inflammation was studied using xylene induced ear edema in mice. The activity of the extracts against chronic inflammation was assessed by formalin-induced edema in the rat paw. In the hot plate tests, intraperitoneal injection of both extracts showed no significant antinociceptive activity in mice. The extracts exhibited antinociceptive activity against acetic acid induced writhing. Naloxone partially blocked only the antinociceptive activity of the stigma aqueous extract. Only the stigma extracts showed weak to moderate effect against acute inflammation. In chronic inflammation, both aqueous and ethanolic stigma extracts, as well as ethanolic petal extract, exerted anti-inflammatory effects. /The authors/ conclude that aqueous and ethanolic extracts of saffron stigma and petal have an antinociceptive effect, as well as acute and/or chronic anti-inflammatory activity. /Stigma extracts/
PMID:11914135 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101384 Hosseinzadeh H, Younesi HM.; BMC Pharmacol. 2: 7 (2002)
EXPL THER Administration of a monthly intramuscular injection of crocetin (dose not specified) to rabbits fed an atherosclerosis-inducing diet reduced serum cholesterol concentrations by 50%, and reduced the severity of atherosclerosis by ~30%. /Crocetin/
WHO Monographs on selected medicinal plants 3: 126-135 (2007); Available from, as of October 23, 2013: https://apps.who.int/medicinedocs/en/m/abstract/Js14213e/
EXPL THER The antioxidant effects of the stigmas were assessed in a clinical trial involving 30 subjects in three groups: 10 healthy volunteers, 10 patients with coronary artery disease and 10 healthy controls. The two test groups received 50 mg of Stigma Croci in 100.0 mL of milk twice daily for 6 weeks, the controls received milk only. Lipoprotein oxidation in blood samples decreased by 42.3% in healthy volunteers (P < 0.001) and 37.9% (P < 0.01) in patients with coronary artery disease compared with controls. /Stigma Croci/
WHO Monographs on selected medicinal plants 3: 126-135 (2007); Available from, as of October 23, 2013: https://apps.who.int/medicinedocs/en/m/abstract/Js14213e/
For more Therapeutic Uses (Complete) data for SAFFRON OIL (7 total), please visit the HSDB record page.
At doses of 5.0 g or more, Stigma Croci may cause serious adverse reactions. Overdose of Stigma Croci (12.0-20.0 g/day) may be fatal. /Stigma Croci/
WHO Monographs on selected medicinal plants 3: 126-135 (2007); Available from, as of October 23, 2013: https://apps.who.int/medicinedocs/en/m/abstract/Js14213e/
Stigma Croci may induce uterine contractions and is therefore contraindicated during pregnancy. Owing to a lack of safety data, use of the stigmas in children and nursing mothers should be restricted to normal food use. Stigma Croci is contraindicated in bleeding disorders. /Stigma Croci/
WHO Monographs on selected medicinal plants 3: 126-135 (2007); Available from, as of October 23, 2013: https://apps.who.int/medicinedocs/en/m/abstract/Js14213e/
Stigma Croci inhibits platelet aggregation and should therefore be used with caution in patients taking anticoagulant or antiplatelet drugs. /Stigma Croci/
WHO Monographs on selected medicinal plants 3: 126-135 (2007); Available from, as of October 23, 2013: https://apps.who.int/medicinedocs/en/m/abstract/Js14213e/
The lethal dose of Stigma Croci is reported to be 20.0 g... /Stigma Croci/
WHO Monographs on selected medicinal plants 3: 126-135 (2007); Available from, as of October 23, 2013: https://apps.who.int/medicinedocs/en/m/abstract/Js14213e/
ABOUT THIS PAGE
47
PharmaCompass offers a list of Transcrocetin Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Transcrocetin Sodium manufacturer or Transcrocetin Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Transcrocetin Sodium manufacturer or Transcrocetin Sodium supplier.
PharmaCompass also assists you with knowing the Transcrocetin Sodium API Price utilized in the formulation of products. Transcrocetin Sodium API Price is not always fixed or binding as the Transcrocetin Sodium Price is obtained through a variety of data sources. The Transcrocetin Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 8022-19-3 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 8022-19-3, including repackagers and relabelers. The FDA regulates 8022-19-3 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 8022-19-3 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 8022-19-3 supplier is an individual or a company that provides 8022-19-3 active pharmaceutical ingredient (API) or 8022-19-3 finished formulations upon request. The 8022-19-3 suppliers may include 8022-19-3 API manufacturers, exporters, distributors and traders.
8022-19-3 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 8022-19-3 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 8022-19-3 GMP manufacturer or 8022-19-3 GMP API supplier for your needs.
A 8022-19-3 CoA (Certificate of Analysis) is a formal document that attests to 8022-19-3's compliance with 8022-19-3 specifications and serves as a tool for batch-level quality control.
8022-19-3 CoA mostly includes findings from lab analyses of a specific batch. For each 8022-19-3 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
8022-19-3 may be tested according to a variety of international standards, such as European Pharmacopoeia (8022-19-3 EP), 8022-19-3 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (8022-19-3 USP).
